Literature DB >> 21666581

Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.

Damon Reed1, Soner Altiok.   

Abstract

BACKGROUND: Soft tissue sarcoma (STS) includes biologically and histologically diverse mesenchymal tumors that are relatively chemotherapy-resistant compared with other sarcoma subtypes.
METHODS: The authors discuss the clinical challenges frequently encountered by medical oncologists and review the literature for predictive strategies to systematically approach chemotherapy decision making.
RESULTS: There are no clinically validated predictive tests for chemotherapeutic response or resistance in STS. Clinical features including histology, stage, and patient age are currently used to guide therapy decisions in STS.
CONCLUSIONS: A method to predict response or resistance to chemotherapy, utilizing both targeted and conventional agents, would be beneficial in reducing toxicity and improving response rates for patients with STS and also in designing clinical trials for this disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21666581     DOI: 10.1177/107327481101800306

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  8 in total

1.  Feasibility and clinical value of CT-guided 125I brachytherapy for metastatic soft tissue sarcoma after first-line chemotherapy failure.

Authors:  Zhiqiang Mo; Tao Zhang; Yanling Zhang; Zhanwang Xiang; Huzhen Yan; Zhihui Zhong; Fei Gao; Fujun Zhang
Journal:  Eur Radiol       Date:  2017-09-27       Impact factor: 5.315

2.  The formation of tight tumor clusters affects the efficacy of cell cycle inhibitors: a hybrid model study.

Authors:  Munju Kim; Damon Reed; Katarzyna A Rejniak
Journal:  J Theor Biol       Date:  2014-03-05       Impact factor: 2.691

3.  PLOD Family: A Novel Biomarker for Prognosis and Personalized Treatment in Soft Tissue Sarcoma.

Authors:  Siming Gong; Nikolas Schopow; Yingjuan Duan; Changwu Wu; Sonja Kallendrusch; Georg Osterhoff
Journal:  Genes (Basel)       Date:  2022-04-28       Impact factor: 4.141

4.  Unraveling novel TF-miRNA regulatory crosstalk in metastasis of Soft Tissue Sarcoma.

Authors:  Devyani Samantarrai; Mousumi Sahu; Jyoti Roy; Bedanta Ballav Mohanty; Garima Singh; Chandra Bhushan; Bibekanand Mallick
Journal:  Sci Rep       Date:  2015-05-18       Impact factor: 4.379

5.  Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets.

Authors:  David G Covell; Anders Wallqvist; Susan Kenney; David T Vistica
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

6.  Rapid screening of novel agents for combination therapy in sarcomas.

Authors:  Christopher L Cubitt; Jiliana Menth; Jana Dawson; Gary V Martinez; Parastou Foroutan; David L Morse; Marilyn M Bui; G Douglas Letson; Daniel M Sullivan; Damon R Reed
Journal:  Sarcoma       Date:  2013-10-24

Review 7.  Sarcoma-The standard-bearer in cancer discovery.

Authors:  Jared W Potter; Kevin B Jones; Jared J Barrott
Journal:  Crit Rev Oncol Hematol       Date:  2018-03-29       Impact factor: 6.312

8.  Combination Therapy with Disulfiram, Copper, and Doxorubicin for Osteosarcoma: In Vitro Support for a Novel Drug Repurposing Strategy.

Authors:  Jonathan B Mandell; Feiqi Lu; Matthew Fisch; Jan H Beumer; Jianxia Guo; Rebecca J Watters; Kurt R Weiss
Journal:  Sarcoma       Date:  2019-07-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.